Von Hippel-lindau Syndrome: Disease Bioinformatics
Von Hippel-Lindau syndrome is an autosomal dominant genetic condition that causes tumors, called hemangioblastomas, in the brain, spinal cord, and eye. The syndrome is caused by a mutation in the VHL gene, which usually acts as a tumor suppressor. When the VHL gene is mutated, rapid growth is no longer regulated and tumors therefore begin to grow. Von Hippel-Lindau syndrome also increases the risk of developing a specific type of kidney cancer known as clear cell renal cell carcinoma. Symptoms of Von Hippel-Lindau syndrome include multiple hemangioblastomas or cysts in the brain, spinal cord, eye, or kidney. Genetic testing is used to diagnose individuals with the disease. Surgery and targeted cancer treatment is used to treat kidney cancer. The hemangioblastomas are often benign and therefore only need to be removed if the tumor interferes with the function of the organ. There is no cure for Von Hippel-Lindau syndrome yet, but focus on cancer research can help to uncover a cure.
Von Hippel-lindau Syndrome Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Von Hippel-lindau Syndrome below!
For more information on how to use Laverne, please read the How to Guide.
We have 2080 products for the study of Von Hippel-lindau Syndrome that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Chromatin Immunoprecipitation (ChIP), Immunohistochemistry from our catalog of antibodies and ELISA kits.
Von Hippel-lindau Syndrome is also known as Cerebroretinal Angiomatosis, Hippel Lindau Disease, Hippel Lindau Syndrome, Hippel-lindau Disease, Lindau Disease.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.